Cell therapy combo aims to boost kidney cancer treatment
NCT ID NCT07087158
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests whether adding an experimental cell therapy called IBR854 to the standard drug pazopanib works better than pazopanib alone for advanced kidney cancer. About 30 adults with untreated advanced clear cell renal cell carcinoma will take part. The goal is to see if the combination slows cancer growth and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBR854 (a cell therapy) combined with pazopanib (a targeted drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced kidney cancer that hasn't been treated before.
What could go wrong
This is an early phase 2 trial with only 30 participants, so results may not apply broadly. Cell therapies can cause serious side effects like immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cadonilimab & Axitinib for Advanced Kidney Cance NCT05256472
- VMD-102 Trial for Advanced Solid Tumors (NCT07636785)
- Toripalimab MRD Study in High-Risk RCC NCT07657325
- CD70 T-Cell Therapy for Kidney Cancer Trial NCT07647744
- CASPIAN: Clampless Sutureless Kidney Surgery for NCT06722807
- Neoadjuvant Anlotinib + Benmelstobart for RCC (NCT07627464)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Cancer Hospital of Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••